Lung cancer vaccines

Current Gene Therapy

Volumn 7, Issue 6, 2007, Pages 469-484

  Eager, Rob ^a,d   Harle, Lindsey ^d   Nemunaitis, John J ^a,b,c,e  

^a Mary Crowley Medical Research Center   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e NONE   (United States)

Author keywords

Cancer; Clinical; Gene; Immune; Lung; Response; Therapy; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA(1,3) GALACTOSYLTRANSFERASE; B7 ANTIGEN; CANCER VACCINE; CYCLOPHILIN B; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DENDRITIC CELL VACCINE; DEXOSOMES; EP 2101; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GALACTOSYLTRANSFERASE; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GV 1001; HR 2822; L 523S; L BLP 25; LUCANIX; MELANOMA ANTIGEN 3; MUCIN 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOVIRUS; ADVANCED CANCER; ANOREXIA; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARM SWELLING; ARTHRALGIA; ASCITES; BONE MARROW TOXICITY; BONE PAIN; BRADYCARDIA; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COHORT ANALYSIS; COUGHING; DELAYED HYPERSENSITIVITY; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL TOXICITY; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAIN; PERICARDIAL EFFUSION; PLEURA EFFUSION; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INDURATION; SKIN IRRITATION; SKIN MANIFESTATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VOMITING; XEROSTOMIA;

CANCER VACCINES; HUMANS; LUNG NEOPLASMS;

EID: 37249054546     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652307782793504     Document Type: Review

References (195)

1. Aguiar, J.C., Hedstrom, R.C., Rogers, W.O., Charoenvit, Y., Sacci, J.B., Jr., Lanar, D.E., Majam, V.F., Stout, R.R. and Hoffman, S.L. (2001). Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine, 20, 275-80.
2. Akbari, O., DeKruyff, R.H. and Umetsu, D.T. (2001). Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol., 2, 725-31.
3. Albain, K.S., Crowley, J.J. and Livingston, R.B. (1991). Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest, 99, 1425-32.
4. Alexandroff, A.B., Jackson, A.M., O'Donnell, M.A. and James, K. (1999). BCG immunotherapy of bladder cancer: 20 years on. Lancet, 353, 1689-94.
5. Antonia, S.J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.H., Menander, K., Chada, S. and Gabrilovich, D.I. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res., 12, 878-87.
6. Antonia, S.J., Seigne, J., Diaz, J., Muro-Cacho, C., Extermann, M., Farmelo, M.J., Friberg, M., Alsarraj, M., Mahany, J.J., Pow-Sang, J., Cantor, A. and Janssen, W. (2002). Phase I trial of a B7-1 (CD80). gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol., 167, 1995-2000.
7. + T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. J. Immunol., 172, 3289-3296.
8. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B. and Palucka, K. (2000). Immunobiology of dendritic cells. Annu. Rev. Immunol., 18, 767-811.
9. Bergsma, D.J., Eder, C., Gross, M., Kersten, H., Sylvester, D., Appelbaum, E., Cusimano, D., Livi, G.P., McLaughlin, M.M., Kasyan, K. and et al., (1991). The cyclophilin multigene family of peptidyl-prolyl isomerases. Characterization of three separate human isoforms. J. Biol. Chem., 266, 23204-14.
10. Bezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., Ayoub, J., Lago, S., de Albuquerque Ribeiro, R., Gerogianni, A., Cyjon, A., Noble, J., Laberge, F., Chan, R.T., Fenton, D., von Pawel, J., Reek, M. and Shepherd, F.A. (2006). Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol., 24, 3831-7.
11. Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I. and Fontana, A. (1989). Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol., 143, 3222-9.
12. Bodner, S.M., Minna, J.D., Jensen, S.M., D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Buchhagen, D.L., Nau, M.M., Gazdar, A.F. and et al., (1992). Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7, 743-9.
13. Border, W.A. and Ruoslahti, E. (1992). Transforming growth factor-beta in disease: the dark side of tissue repair. J. Clin. Invest., 90, 1-7.
14. Brezicka, F.T., Oiling, S., Nilsson, O., Bergh, J., Holmgren, J., Sorenson, S., Yngvason, F. and Lindholm, L. (1989). Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res., 49, 1300-5.
15. Brezicka, T., Bergman, B., Olling, S. and Fredman, P. (2000). Reactivity of monoclonal antibodies w3ith ganglioside antigens in human small cell lung cancer tissues. Lung Cancer, 28, 29-36.
16. Brunsvig, P.F., Aamdal, S., Gjertsen, M.K., Kvalheim, G., Markowski-Grimsrud, C.J., Sve, I., Dyrhaug, M., Trachsel, S., Moller, M., Eriksen, J.A. and Gaudernack, G. (2006). Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother., 55, 1553-64.
17. Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R. and Larnport, D. (1987). Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47, 5476-82.
18. Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulieres, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., Davis, M., Mansi, J., Smith, C., Vergidis, D., Ellis, P., MacNeil, M. and Palmer, M. (2005). Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol., 23, 6674-81.
19. Caldarella, A., Crocetti, E., Comin, C.E., Janni, A., Pegna, A.L. and Paci, E. (2006). Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications. Cancer, 107, 793-8.
20. Conrad, C. and Nestle, F.O. (2003). Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther., 5, 405-12.
21. Constam, D.B., Philipp, J., Malipiero, U.V., ten Dijke, P., Schachner, M. and Fontana, A. (1992). Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol., 148, 1404-10.
22. Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A. and Wilt, T. (2005). Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev., CD001425.
23. Coulie, P.G., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V. and Boon, T. (2001). A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA, 98, 10290-5.
24. Cranmer, L.D., Trevor, K.T. and Hersh, E.M. (2004). Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother., 53, 275-306.
25. D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R. and et al., (1992). High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7, 339-46.
26. Daniel, L., Ttouillas, J., Renaud, W., Chevallier, P., Gouvernet, J., Rougon, G. and Figarella-Branger, D. (2000). Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats). is related to growth rate and malignancy. Cancer Res., 60, 80-5.
27. Denzer K, v.E.M., Kleijmeer M.J., et al., (2000). Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J. Immunol., 165, 1259-65.
28. Dickler, M.N., Ragupathi, G., Liu, N.X., Musselli, C., Martino, D.J., Miller, V.A., Kris, M.G., Brezicka, F.T., Livingston, P.O. and Grant, S.C. (1999). Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res., 5, 2773-9.
29. Dippold, W.G., Dienes, H.P., Knuth, A. and Meyer zam Buschenfelde, K.H. (1985). Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res., 45, 3699-705.
30. Disis, M.L., Calenoff, E., McLaughlin, G., Murphy, A.E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R.B. and et al., (1994). Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54, 16-20.
31. Dohadwala, M., Lon, J., Zhu, L., Lin, Y., Dougherty, G.J., Sharma, S., Huang, M., Pold, M., Batra, R.K. and Dubinett, S.M. (2001). Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem., 276, 20809-12.
32. Dorigo, O., Shawler, D.L., Royston, I., Sobol, R.E., Berek, J.S. and Fakhrai, H. (1998). Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol. Oncol., 71, 204-10.
33. Drummond, I.A., Madden, S.L., Rohwer-Nutter, P., Bell, G.I., Sukhatme, V.P. and Rauscher, F.J., 3rd. (1992). Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science, 257, 674-8.
34. Eton, O., Legha, S.S., Bedikian, A.Y., Lee, J.J., Buzaid, A.C., Hodges, C., Ring, S.E., Papadopoulos, N.E., Plager, C., East, M.J., Zhan, F. and Benjamin, R.S. (2002). Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J. Clin. Oncol., 20, 2045-52.
35. Fakbrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D., Black, K.L., Royston, I. and Sobol, R.E. (1996). Eradication of established intracranial rat ghomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93, 2909-14.
36. Fakhtai, H., Mantil, J.C., Liu, L., Nicholson, G.L., Murphy-Satter, C.S., Ruppert, J. and Sbawler, D.L. (2006). Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther., 13, 1052-60.
37. Ferries, E., Connan, F., Pages, F., Gaston, J., Hagnere, A.M., Vieillefond, A., Thiounn, N., Guillet, J. and Choppin, J. (2001). Identification of p53 peptides recognized by CD8(+). T lymphocytes from patients with bladder cancer. Hum. Immunol., 62, 791-8.
38. Finne, J., Finne, U., Deagostini-Bazin, H. and Goridis, C. (1983). Occurrence of alpha 2-8 linked polysialosyl units in a neural cell adhesion molecule. Biochem. Biophys. Res. Commun., 112, 482-7.
39. Fleischhauer, K., Fruci, D., Van Endert, P., Herman, J., Tanzarella, S., Wallny, H.J., Coolie, P., Bordignon, C. and Traversari, C. (1996). Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int. J Cancer, 68, 622-8.
40. Fontana, A., Frei, K., Bodmer, S., Hofer, E., Schreier, M.H., Palladino, M.A., Jr. and Zinkernagel, R.M. (1989). Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol., 143, 3230-4.
41. Fossella, F.V., DeVore, R., Kerr, R.N., Crawford, J., Natale, R.R., Dunphy, F., Kalman, L., Miller, V., Lee, J.S., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F. and Hammershaimb, L. (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol., 18, 2354-62.
42. Fry, W.A., Phillips, J.L. and Menck, H.R. (1999). Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer, 86, 1867-76.
43. Fuentes, R., Allman, R. and Mason, M.D. (1997). Ganglioside expression in lung cancer cell lines. Lung Cancer, 18, 21-33.
44. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J.J., De Plaen, E., Lethe, B., Brasseur, F. and Boon, T. (1994). Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp. Med., 179, 921-30.
45. Gendler, S.J., Lancaster, C.A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Lalani, E.N. and Wilson, D. (1990). Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem., 265, 15286-93.
46. Germain, R.N. (1994). MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell, 76, 287-99.
47. Gilboa, E., Nair, S.K. and Lyerly, H.K. (1998). Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother., 46, 82-7.
48. Gohara, R., Imai, N., Rikimaru, T., Yamada, A., Hida, N., Ichiki, M., Kawamoto, M., Matsunaga, K., Ashihara, J., Yano, S., Tamura, M., Ohkouchi, S., Yamana, H., Oizumi, K. and Itoh, K. (2002). Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J. Immunother., 25, 439-44.
49. Gomi, S., Nakao, M., Niiya, F., Imamura, Y., Kawano, K., Nishizaka, S., Hayashi, A., Sobao, Y., Oizumi, K. and Itoh, K. (1999). A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J. Immunol., 163, 4994-5004.
50. Gonzalez, G., Crombet, T., Catala, M., Mirabal, V., Hernandez, J.C., Gonzalez, Y., Marinello, P., Guillen, G. and Lage, A. (1998). A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol., 9, 431-5.
51. Gonzalez, G., Crombet, T., Neninger, E., Viada, C. and Lage, A. (2007). Therapeutic vaccination with epidermal growth factor (EGF). in advanced lung cancer: analysis of pooled data from three clinical trials. Hum. Vaccin., 3, 8-13.
52. Gonzalez, G., Crombet T., Torres F., et al., (2003). Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol., 14, 461-466.
53. Goodyer, P., Dehbi, M., Torban, E., Bruening, W. and Pelletier, J. (1995). Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene, 10, 1125-9.
54. Grant, S.C., Kris, M.G., Houghton, A.N. and Chapman, P.B. (1999). Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res., 5, 1319-23.
55. Graus, F., Cordon-Cardo, C., Houghton, A.N., Melamed, M.R. and Old, L.J. (1984). Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody. Brain Res., 324, 190-4.
56. Halmos, B.H. (2006). Lung Cancer II. ASCO Annual Meeting Summaries, 156-160.
57. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, Manegold, C., Paul, S., Paoletti, P., Einhom, L. and Bunn, P.A., Jr. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol., 22, 1589-97.
58. Hege, K.M. and Carbone, D.P. (2003). Lung cancer vaccines and gene therapy. Lung Cancer, 41 Suppl. 1, S103-13.
59. Herman, J., van der Bruggen, P., Luescher, I.F., Mandruzzato, S., Romero, P., Thonnard, J., Fleischhauer, K., Boon, T. and Coulie, P.G. (1996). A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics, 43, 377-83.
60. Hewitt, S.M., Hamada, S., McDonnell, T.J., Rauscher, F.J.3rd. and Saunders, G.F. (1995). Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms'tumor suppressor gene WT1. Cancer Res., 55, 5386-9.
61. Hirschowitz, E.A., Foody, T., Kryscio, R., Dickson, L., Sturgill, J. and Yannelli, J. (2004). Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol., 22, 2808-15.
62. Hirte, H. and Clark, D.A. (1991). Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol. Immunother., 32, 296-302.
63. Hirte, H.W., Clark, D.A., O'Connell, G., Rusthoven, J. and Mazurka, J. (1992). Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol., 142, 207-16.
64. Horig, H., Lee, D.S., Conkright, W., Divito, J., Hasson, H., LaMare, M., Rivera, A., Park, D., Tine, J., Guito, K., Tsang, K.W., Schlom, J. and Kaufman, H.L. (2000). Phase I clinical trial of a recombinant canary-poxvirus (ALVAC). vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother., 49, 504-14.
65. Hsu, D.H., Paz, P., Villaflor, G., Rivas, A., Mehta-Damani, A., Angevin, E., Zitvogel, L. and Le Pecq, J.B. (2003). Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother., 26, 440-50.
66. Hull, G.W., McCurdy, M.A., Nasu, Y., Bangma, C.H., Yang, G., Shimura, S., Lee, H.M., Wang, J., Albani, J., Ebara, S., Sato, T., Timme, T.L. and Thompson, T.C. (2000). Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin. Cancer Res., 6, 4101-9.
67. Ihde, D.C. and Minna, J.D. (1991). Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr. Probl. Cancer, 15, 61-104.
68. Ishida, T., Chada, S., Stipanov, M., Nadaf, S., Ciernik, F.I., Gabrilovich, D.I. and Carbone, D.P. (1999). Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin. Exp. Immunol., 117, 244-51.
69. Jakowlew, S.B., Mathias, A., Chung, P. and Moody, T.W. (1995). Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ., 6, 465-76.
70. Jassem, J., Skokowski, J., Dziadziuszko, R., Jassem, E., Szymanowska, A., Rzyman, W. and Roszkiewicz, A. (2000). Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J. Thorac. Cardiovasc. Surg., 119, 1141-6.
71. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. and Thun, M.J. (2006). Cancer statistics, 2006. CA Cancer J. Clin., 56, 106-30.
72. Jennings, H.J., Roy, R. and Gamian, A. (1986). Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol., 137, 1708-13.
73. Johnston, J.V., Malacko, A.R., Mizano, M.T., McGowan, P., Hellstrom, I., Hellstrom, K.E., Marquardt, H. and Chen, L. (1996). B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med., 183, 791-800.
74. Kaplan, J.M. (2005). Adenovirus-based cancer gene therapy. Curr. Gene. Ther., 5, 595-605.
75. Kasid, A., Bell, G.I. and Director, E.P. (1988). Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol., 141, 690-8.
76. Kaufman, H.L., Wang, W., Manola, J., DiPaola, R.S., Ko, Y.J., Sweeney, C., Whiteside, T.L., Schlom, J., Wilding, G. and Weiner, L.M. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol., 22, 2122-32.
77. Kawashima, I., S. J. Hudson, V. Tsai, et al., (1998). The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various trumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol., 59, 1-14.
78. Keilholz, U., Weber, J., Finke, J.H., Gabrilovich, D.I., Kast, W.M., Disis, M.L., Kirkwood, J.M., Scheibenbogen, C., Schlom, J., Maino, V.C., Lyerly, H.K., Lee, P.P., Storkus, W., Marincola, F., Worobec, A. and Atkins, M.B. (2002). Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother., 25, 97-138.
79. Keogh, E., Fikes, J., Southwood, S., Celis, E., Chesnut, R. and Sette, A. (2001). Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A *0201-binding affinity. J. Immunol., 167, 787-96.
80. Kettering, J.D., Mohamedali, A.M., Green, L.M. and Gridley, D.S. (2003). IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression. Technol. Cancer Res. Treat., 2, 211-21.
81. Knutson, K.L., Schiffman, K. and Disis, M.L. (2001). Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest., 107, 477-84.
82. Komminoth, P., Roth, J., Lackie, P.M., Bitter-Suermann, D. and Heitz, P.U. (1991). Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am. J. Pathol., 139, 297-304.
83. Kong, F., Jirtle, R.L., Huang, D.H., Clough, R.W. and Anscher, M.S. (1999). Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer, 86, 1712-9.
84. Kris, M.G., Natale, R.B., Herbst, R.S., Lynch, T.J., Jr., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J. and Kay, A.C. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-58.
85. Krug, L.M., Ragupathi, G., Hood, C., Kris, M.G., Miller, V.A., Allen, JR., Keding, S.J., Danishefsky, S.J., Gomez, J., Tyson, L., Pizzo, B., Baez, V. and Livingston, P.O. (2004a). Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res., 10, 6094-100.
86. Krug, L.M., Ragupathi, G., Ng, K.K., Hood, C., Jennings, H.J., Guo, Z., Kris, M.G., Miller, V., Pizzo, B., Tyson, L., Baez, V. and Livingston, P.O. (2004b). Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin. Cancer Res., 10, 916-23.
87. Kufé, D., Inghirami, G., Abe, M., Hayes, D., Justi-Wheeler, H. and Schlom, J. (1984). Differential reactivity of a novel monoclonal antibody (DF3), with human malignant versus benign breast tumors. Hybridoma, 3, 223-32.
88. Kwak, L.W. (2003). Translational development of active immunotherapy for hematologic malignancies. Semin. Oncol., 30, 17-22.
89. Lantuejoul, S., Moro, D., Michalides, R.J., Brambilla, C. and Brambilla, E. (1998). Neural cell adhesion molecules (NCAM). and NCAM-PSA expression in neuroendocrine lung tumors. Am. J. Surg. Pathol., 22, 1267-76.
90. Lassen, U., Osterlind, K., Hansen, M., Dombernowsky, P., Bergman, B. and Hansen, H.H. (1995). Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J. Clin. Oncol., 13, 1215-20.
91. Leong, S.S., Rocha Lima, C.M., Sherman, C.A. and Green, M.R. (1999). The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest, 115, 242-8.
92. Li, Y., Liu, D., Chen, D., Kharbanda, S. and Kufe, D. (2003). Human DF3/ MUC1 carcinoma-associated protein functions as an oncogene. Oncogene, 22, 6107-10.
93. Liau, L.M., Fakhrai, H. and Black, K.L. (1998). Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol. Res., 20, 742-7.
94. Link, C.J., Jr., Seregina, T., Atchison, R., Hall, A., Muldoon, R. and Levy, J.P. (1998). Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3). galactosyltransferase gene therapy. Anticancer Res., 18, 2301-8.
95. Liu, B., Podack, E.R., Allison, J.P. and Malek, T.R. (1996). Generation of primary tomor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol., 156, 1117-25.
96. Lombardi, G., Sidhu, S., Batchelor, R. and Lechler, R. (1994). Anergic T cells as suppressor cells in vitro. Science, 264, 1587-9.
97. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M.H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P.Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coolie, P. G., van der Bruggen, P. and Boon, T. (1999). Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80, 219-30.
98. Marshall, J.L., Hoyer, R.J., Toomey, M.A., Faraguna, K., Chang, P., Richmond, E., Pedicano, J.E., Gehan, E., Peck, R.A., Arlen, P., Tsang, K.Y. and Schlom, J. (2000). Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol., 18, 3964-73.
99. Marzo, A.L., Fitzpatrick, D.R., Robinson, B.W. and Scott, B. (1997). Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res., 57, 3200-7.
100. Massague, J. (1987). The TGF-beta family of growth and differentiation factors. Cell, 49, 437-8.
101. Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Ce sare, C.M., Appasamy, P.M., Lotze, M.T., Storkus, W.J., Appella, E. and DeLeo, A.B. (1996). Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183, 1357-65.
102. McAdam, A.J., Schweitzer, A.N. and Sharpe, A.H. (1998). The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol. Rev., 165, 231-47.
103. McCaffery, M., Yao, T.J., Williams, L., Livingston, P.O., Houghton, A.N. and Chapman, P.B. (1996). Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res., 2, 679-86.
104. McKinney, D.M., Skvoretz, R., Qin, M., Ishioka, G. and Sette, A. (2000). Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization. J. Immunol. Methods, 237, 105-17.
105. Miyoshi, Y., Ando, A., Egawa, C., Taguchi, T., Tamaki, Y., Tamaki, H., Sugiyama, H. and Noguchi, S. (2002). High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin. Cancer Res., 8, 1167-71.
106. Molina, J.R., Adjei, A.A. and Jett, J.R. (2006). Advances in chemotherapy of non-small cell lung cancer. Chest, 130, 1211-9.
107. Morris, J.C., Vahanian, N., and Janik, J.E. (2005). Phase I study of an anti-tumor vaccination using a(1,3).galactosyltransferase expressing allogeneic tumor cells in patients (Pts). with refractory or recurrent non-small cell lung cancer (NSCLC). J. Clin. Oncol. ASCO Ann. Meet. Proc., 23, 2586.
108. Morse, M.A. (2001). Technology evaluation: BLP-25, Biomira Inc. Curr. Opin. Mol. Ther., 3, 102-5.
109. Morse, M.A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T.M., Valente, N., Shreeniwas, R., Sutton, M.A., Delcayre, A., Hsu, D.H., Le Pecq, J.B. and Lyerly, H.K. (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med., 3, 9.
110. Mueller-Pillasch, F., Pohl, B., Wilda, M., Lacher, U., Beil, M., Wallrapp, C., Hameister, H., Knochel, W., Adler, G. and Gress, T.M. (1999). Expression of the highly conserved RNA binding protein KOC in embryo-genesis. Mech. Dev., 88, 95-9.
111. Nabel, G.J., Gordon, D., Bishop, D.K., Nickoloff, B.J., Yang, Z.Y., Aruga, A., Cameron, M.J., Nabel, E.G. and Chang, A.E. (1996). Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA, 93, 15388-93.
112. Naganuma, H., Sasaki, A., Satoh, E., Nagasaka, M., Nakano, S., Isoe, S., Tasaka, K. and Nukui, H. (1996). Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol. Med. Chir. (Tokyo)., 36, 789-95.
113. Nemunaitis, J., Dillman, R.O., Schwarzenberger, P.O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., DeVol, E., Maples, P.B., Liu, L., Chamberlin, T., Shawler, D.L. and Fakhrai, H. (2006a). Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol., 24, 4721-30.
114. Nemunaitis, J., Jahan, T., Ross, H., Sterman, D., Richards, D., Fox, B., Jablons, D., Aimi, J., Lin, A. and Hege, K. (2006b). Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther., 13, 555-62.
115. Nemunaitis, J., Meyers, T., Senzer, N., Cunningham, C., West, H., Vallieres, E., Anthony, S., Vukelja, S., Berman, B., Tully, H., Pappen, B., Sarmiento, S., Arzaga, R., Duniho, S., Engardt, S., Meagher, M. and Cheever, M.A. (2006c). Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol. Ther., 13, 1185-91.
116. Nemunaitis, J., Sterman, D., Jablons, D., Smith, J.W., 2nd, Fox, B., Maples, P., Hamilton, S., Borellini, F., Lin, A., Morali, S. and Hege, K. (2004). Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst., 96, 326-31.
117. Neunet, A., Schindel, M., Wildenberg, U., Muley, T., Lahm, H. and Fischer, J.R. (2001). Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer, 34 Suppl. 2, S79-82.
118. Neuner, A., Schindel, M., Wildenberg, U., Muley, T., Lahm, H. and Fischer, J.R. (2002). Prognostic significance of cytokine modulation in non-small cell lung cancer. Int. J. Cancer, 101, 287-92.
119. Nikitina, E.Y., Clark, J.I., Van Beynen, J., Chada, S., Virmani, A.K., Carbone, D.P. and Gabrilovich, D.I. (2001). Dendritic, cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res., 7, 127-35.
120. Ohlfest, J.R., Freese, A.B. and Largaespada, D.A. (2005). Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr. Gene Ther., 5, 629-41.
121. Ohminami, H., Yasukawa, M. and Fujita, S. (2000). HLA class I-restricted lysis of leukemia cells by a CD8(+). cytotoxic T-lymphocyte clone specific for WTI peptide. Blood, 95, 286-93.
122. Oiso, M., Eura, M., Katsura, F., Takiguchi, M., Sobao, Y., Masuyama, K., Nakashima, M., Itoh, K. and Ishikawa, T. (1999). A newly identified MAGE-3-derived epitope recognized by HLA-A24-restficted cytotoxic T lymphocytes. Int. J Cancer, 81, 387-94.
123. Oji, Y., Miyoshi, S., Maeda, H., Hayashi, S.,Tamaki, H., Nakatsuka, S., Yao, M., Takahashi, E., Nakano, Y., Hirabayashi, H., Shintani, Y., Oka, Y., Tsuboi, A., Hosen, N., Asada, M., Fujioka, T., Murakami, M., Kanato, K., Motomura, M., Kim, E.H., Kawakami, M., Ikegame, K., Ogawa, H., Aozasa, K., Kawase, I. and Sugiyama, H. (2002). Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int. J Cancer, 100, 297-303.
124. Oka, Y., Elisseeva, O.A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E.H., Soma, T., Asada, M., Ueda, K., Maruya, E., Saji, H., Kishimoto, T., Udaka, K. and Sugiyama, H. (2000). Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1). product. Immunogenetics, 51, 99-107.
125. Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O.A., Oji, Y., Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I. and Sugiyama, H. (2004). Induction of WTI (Wilms' tumor gene).-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl. Acad. Sci. USA, 101, 13885-90.
126. Palmer, M., Parker, J., Modi, S., Butts, C., Smylie, M., Meikle, A., Kehoe, M., MacLean, G. and Longenecker, M. (2001). Phase I study of the BLP25 (MUCI peptide). liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer, 3, 49-57.
127. Park, J.A., Wang, E. Kurt, R.A., Schluter, S.F., Hersh, E.M. and Akporiaye, E.T. (1997). Expression of an antisense transforming growth factor-betal transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther., 4, 42-50.
128. Parkin, D.M., Pisani, P. and Ferlay, J. (1993). Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer, 54, 594-606.
129. Peto, R., Lopez, A.D., Boreham, J., Thun, M. and Heath, C., Jr. (1992). Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet, 339, 1268-78.
130. Pisani, P., Parkin, D.M. and Ferlay, J. (1993). Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer, 55, 891-903.
131. Price, E.R., Zydowsky, L.D., Jin, M.J., Baker, C.H., McKeon, F.D. and Walsh, C.T. (1991). Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci. USA, 88, 1903-7.
132. Pulendran, B., Smith, J.L., Caspary, G., Brasel, K., Pettit, D., Maraskovsky, E. and Maliszewski, C.R. (1999). Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA, 96, 1036-41.
133. Quan, W.D., Jr., Dean, G.E., Spears, L., Spears, C.P., Groshen, S., Merritt, J.A. and Mitchell, M.S. (1997). Active specific immunotherapy
134. Raez, L.E., Cassileth, P.A., Schlesselman, J.J., Sridbar, K., Padmanabhan, S., Fisher, E.Z., Baldie, P.A. and Podack, E.R. (2004). Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 22, 2800-7.
135. Raez, L.E., Santos, E.S., Mudad, R. and Podack E.R. (2005). Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Rev. Anticancer Ther., 5, 635-644.
136. Ramos, T.C., Vinageras, E.N., Ferrer, M.C., Verdecia, B.G., Rupale, I.L., Perez, L.M., Marinello, G.G., Rodriguez, R.P. and Davila, A.L. (2006). Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol. Ther., 5, 145-9.
137. Ranges, G.E., Figari, I.S., Espevik, T. and Palladino, M.A., Jr. (1987). Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J. Exp. Med., 166, 991-8.
138. Raposo, G., Nijman, H.W., Stoorvogel, W., Liejendekker, R., Harding, C.V., Melief, C.J. and Geuze, H.J. (1996). B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med., 183, 1161-72.
139. Ren, J., Agata, N., Chen, D., Li, Y., Yu, W.H., Huang, L., Raina, D., Chen, W., Kharbanda, S. and Kufe, D. (2004). Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell, 5, 163-75.
140. Ribas, A. (2005). Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther., 5, 619-28.
141. Rook, A.H., Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Sporn, M.B., Burlington, D.B., Lane, H.C. and Fauci, A.S. (1986). Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol., 136, 3916-20.
142. Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J.L., Li, S., Roig, J., Olazabal, A. and et al., (1994). A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med., 330, 153-8.
143. Rosenwirth, B., Kuhn, E.M., Heeney, J.L., Hurpin, C., Tartaglia, J., Bonnet, M.C., Moingeon, P. and Erdile, L. (2001). Safety and immunogenicity of ALVAC wild-type human p53 (vCP207). by the intravenous route in rhesus macaques. Vaccine, 19, 1661-70.
144. Roszman, T., Elliott, L. and Brooks, W. (1991). Modulation of T-cell function by gliomas. Immunol. Today, 12, 370-4.
145. Roth, J.A., Fossella, F., Komaki, R., Ryan, M.B., Putnam, J.B., Jr., Lee, J.S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M. and et al., (1994). A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst., 86, 673-80.
146. Ruffini, P.A., Rivoltini, L., Silvani, A., Boiardi, A. and Parmiani, G. (1993). Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol. Immunother., 36, 409-16.
147. Russo, V., Tanzarella, S., Dalerba, P., Rigatti, D., Rovere, P., Villa, A., Bordignon, C. and Traversari, C. (2000). Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class 1-restricted T cell response. Proc. Natl. Acad. Sci. USA, 97, 2185-90.
148. Rutishauser, U. (1998). Polysialic acid at the cell surface: biophysics in service of cell interactions and tissue plasticity. J. Cell Biochem., 70, 304-12.
149. Rutishauser, U. and Landmesser, L. (1996). Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions. Trends Neurosci., 19, 422-7.
150. Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F.S., Jaklitsch, M., Mentzer, S., Swanson, S., Lukanich, J., Bueno, R., Wain, J., Mathisen, D., Wright, C., Fidias, P., Donahue, D., Clift, S., Hardy, S., Neuberg, D., Mulligan, R., Webb, I., Sugarbaker, D., Mihm, M. and Dranoff, G. (2003). Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol., 21, 624-30.
151. Scardino, A., Gross, D.A., Alves, P., Schultze, J.L., Graff-Dubois, S., Faure, O., Tourdot, S., Chouaib, S., Nadler, L.M., Lemonnier, F.A., Vonderheide, R.H., Cardoso, A.A. and Kosmatopoulos, K. (2002). HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol., 168, 5900-6.
152. Schadendorf, D., Paschen, A. and Sun, Y. (2000). Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol. Lett., 74, 67-74.
153. Schroers, R., Shen, L., Rollins, L., Rooney, C.M., Slawin, K., Sonderstrup, G., Huang, X.F. and Chen, S.Y. (2003). Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res., 9, 4743-55.
154. Schultz, E.S., Chapiro, J., Lurquin, C., Claverol, S., Burlet-Schiltz, O., Warnier, G., Russo, V., Morel, S., Levy, F., Boon, T., Van den Eynde, B.J. and van der Bruggen, P. (2002). The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med., 195, 391-9.
155. Schwartz, R.H. (1996). Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med., 184, 1-8.
156. Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y. and Berille, J. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol., 18, 2095-103.
157. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. and Seymour, L. (2005). Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 353, 123-32.
158. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A. and et al., (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
159. Smith, K.A. (1988). Interleukin-2: inception, impact, and implications. Science, 240, 1169-76.
160. Smith, K.A. (1993). Lowest dose interleukin-2 immunotherapy. Blood, 81, 1414-23.
161. Spiegelman, D., Maurer, L.H., Ware, J.H., Perry, M.C., Chahinian, A.P., Comis, R., Eaton, W., Zimmer, B. and Green, M. (1989). Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J. Clin. Oncol., 7, 344-54.
162. Sporn, M.B., Roberts, A.B., Wakefield, L.M. and Assoian, R.K. (1986). Transforming growth factor-beta: biological function and chemical structure. Science, 233, 532-4.
163. Suzuki, K., Nagai, K., Yoshida, J., Moriyama, E., Nishimura, M., Takahashi, K. and Nishiwaki, Y. (1999). Prognostic factors in clinical stage I non-small cell lung cancer. Ann. Thorac. Surg., 67, 927-32.
164. Tahara, H., Yasui, W., Tahara, E., Fujimoto, J., Ito, K., Tamai, K., Nakayama, J., Ishikawa, F., Tahara, E. and Ide, T. (1999). Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene, 18, 1561-7.
165. Tanaka, F., Fujie, T., Tahara, K., Mori, M., Takesako, K., Sette, A., Celis, E. and Akiyoshi, T. (1997). Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res., 57, 4465-8.
166. Tanzarella, S., Russo, V., Lionello, I., Dalerba, P., Rigatti, D., Bordignon, C. and Traversari, C. (1999). Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res., 59, 2668-74.
167. Tartaglia, J., Bonnet, M.C., Berinstein, N., Barber, B., Klein, M. and Moingeon, P. (2001). Therapeutic vaccines against melanoma and colorectal cancer. Vaccine, 19, 2571-5.
168. Ten Have-Opbroek, A.A., Benfield, J.R., Hammond, W.G., Teplitz, R.L. and Dijkman, J.H. (1994). In favour of an oncofoetal concept of bronchogenic carcinoma development. Histol. Histopathol., 9, 375-84.
169. Thery C, D.L., Sergura, E., et al., (2002). Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol., 3, 1156-62.
170. Thery C, R.A., Garin J, et al., (1999). Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J. Cell Biol., 147, 599-610.
171. Tigges, M.A., Casey, L.S. and Koshland, M.E. (1989). Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway. Science, 243, 781-6.
172. Timmerman, J.M. and Levy, R. (1999). Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med., 50, 507-29.
173. Toloza, E.M., Roth, J.A. and Swisher, S.G. (2000). Molecular events in bronchogenic carcinoma and their implications for therapy. Semin. Surg. Oncol., 18, 91-9.
174. Tsao, M.S., Sakurada, A., Cutz, J.C., Zhu, C.Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., Marrano, P., da Cunha Santos, G., Lagarde, A., Richardson, F., Seymour, L., Whitehead, M., Ding, K., Pater, J. and Shepherd, F.A. (2005). Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med., 353, 133-44.
175. Tsunawaki, S., Sporn, M., Ding, A. and Nathan, C. (1988). Deactivation of macrophages by transforming growth factor-beta. Nature, 334, 260-2.
176. Tzai, T.S., Lin, C.I., Shiau, A.L. and Wu, C.L. (1998). Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res., 18, 1585-9.
177. Tzai, T.S., Shiau, A.L., Liu, L.L. and Wu, C.L. (2000). Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res., 20, 1557-62.
178. Uchida, N., Otsuka, T., Shigematsu, H., Maeda, M., Sugio, Y., Itoh, Y. and Niho, Y. (1999). Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk. Res., 23, 1127-32.
179. Van den Eynde, B.J. and van der Bruggen, P. (1997). T cell defined tumor antigens. Curr. Opin. Immunol., 9, 684-93.
180. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P.G., Boel, P., De Smet, C., Traversari, C., Townsend, A. and Boon, T. (1994). A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24, 3038-43.
181. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-7.
182. Vangsted, A.J., Clausen, H., Kjeldsen, T.B., White, T., Sweeney, B., Hakomori, S., Drivsholm, L. and Zeuthen, J. (1991). Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1). antigen in serum. Cancer Res., 51, 2879-84.
183. Vitiello, A., Marchesini, D., Furze, J., Sherman, L.A. and Chesnut, R.W. (1991). Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med., 173, 1007-15.
184. von Mehren, M., Arlen, P., Tsang, K.Y., Rogatko, A., Meropol, N., Cooper, H.S., Davey, M., McLaughlin, S., Schlom, J. and Weiner, L.M. (2000). Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA). and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res., 6, 2219-28.
185. Vonderheide, R.H., Anderson, K.S., Hahn, W.C., Butler, M.O., Schultze, J.L. and Nadler, L.M. (2001). Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res., 7, 3343-8.
186. Vonderheide, R.H., Hahn, W.C., Schultze, J.L. and Nadler, L.M. (1999). The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10, 673-9.
187. Welte, K., Miller, G., Chapman, P.B., Yuasa, H., Natoli, E., Kunicka, J.E., Cordon-Cardo, C., Buhrer, C., Old, L.J. and Houghton, A.N. (1987). Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J. Immunol., 139, 1763-71.
188. Wentworth, P.A., Vitiello, A., Sidney, J., Keogh, E., Chesnut, R.W., Grey, H. and Sette, A. (1996). Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol., 26, 97-101.
189. Woo, E.Y., Chu, C.S., Goletz, T.J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S.C., Kaiser, L.R. and June, C.H. (2001). Regulatory CD4(+).CD25(+). T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res., 61, 4766-72.
190. Woo, E.Y., Yeh, H., Chu, C.S., Schlienger, K., Carroll, R.G., Riley, J.L., Kaiser, L.R. and June, C.H. (2002). Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol., 168, 4272-6.
191. Yano, T., Yokoyama, H., Inoue, T., Asoh, H., Tayama, K. and Ichinose, Y. (1994). Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J. Thorac. Cardiovasc. Surg., 107, 1398-402.
192. Zajac, P., Oertli, D., Marti, W., Adamina, M., Bolli, M., Guller, U., Noppen, C., Padovan, E., Schultz-Thater, E., Heberer, M. and Spagnoli, G. (2003). Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther., 14, 1497-510.
193. Zaremba, S., Barzaga, E., Zhu, M., Soares, N., Tsang, K.Y. and Schlom, J. (1997). Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res., 57, 4570-7.
194. Zhang, S., Cordon-Cardo, C., Zhang, H.S., Reuter, V.E., Adluri, S., Hamilton, W.B., Lloyd, K.O. and Livingston, P.O. (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J Cancer, 73, 42-9.
195. Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-Castagnoli, P., Raposo, G. and Amigorena, S. (1998). Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med., 4, 594-600.